Search Results
Nov 03, 2025, 19:37 ET Health Union Expands Custom Insights Solutions for Patients and Providers
The suite is newly enhanced to incorporate high-value patient, caregiver, and HCP voices in unique ways. By leveraging proprietary data from Health Union's online community platforms and recently acquired HCP database, diverse methodologies, and specialized therapeutic area expertise, these solutions
More news about: Health Union
Nov 03, 2025, 09:30 ET Verix Secures U.S. Patent for Dynamic Code Technology Enabling Intelligent Automation in its Flagship Tovana™ Platform
Life Sciences organizations. Tovana leverages AI, dynamic code automation, and deep domain expertise to optimize critical commercial operations such as HCP targeting, precision forecasting, omnichannel optimization, and patient discovery. By unifying advanced data science with adaptive
More news about: Verix
Nov 03, 2025, 09:00 ET Apptio Unveils Next-Generation FinOps Solutions Designed to Redefine How Cloud Leaders Manage and Optimize Investments in the AI Era
financial impact of their infrastructure decisions. Backed by Cloudability and now integrated with HashiCorp Cloud Platform (HCP) and Hashicorp Terraform, Cloudability Governance is specifically designed to empower FinOps teams with greater control over cloud infrastructure deployments
More news about: Apptio
Nov 03, 2025, 04:00 ET Anthill Cloud : transformer le marketing pharmaceutique avec l'IA, le contenu modulaire et l'engagement omnicanal
Cloud unifie la création de contenu, la gouvernance et l'activation omnicanale, accélère le temps de mise sur le marché et augmente l'engagement des HCP.
More news about: Anthill A/S
Nov 03, 2025, 04:00 ET Anthill Cloud: Transforming Pharma Marketing with AI, Modular Content, and Omnichannel Engagement
for Pharma, MedTech, and Biotech, Anthill Cloud unifies content creation, governance, and omnichannel activation, accelerates time-to-market, and elevates HCP engagement.
More news about: Anthill A/S
Nov 03, 2025, 04:00 ET Anthill Cloud: Transforming Pharma Marketing with AI, Modular Content, and Omnichannel Engagement
for Pharma, MedTech, and Biotech, Anthill Cloud unifies content creation, governance, and omnichannel activation, accelerates time-to-market, and elevates HCP engagement.
More news about: Anthill A/S
Oct 30, 2025, 10:02 ET Doceree Recognized by OpenAI for Crossing 10 Billion Tokens, Reinforcing its Leadership in AI-Driven Healthcare Marketing
Operating System for healthcare marketing. We believe the role of AI is to bring richer context to every HCP interaction. Hence, our patented AI understands multiple layers of context to enhance every HCP interaction in a privacy-compliant manner, delivering measurably better outcomes every time. In just
More news about: Doceree Inc.
Oct 30, 2025, 10:01 ET WebMD Ignite Launches Pulse to Help Health Systems Thrive in an AI Efficiency-First Era
data-driven approach designed to help health systems target smarter, move faster and prove value across the entire patient and healthcare provider (HCP) journey. "Healthcare marketing is facing a perfect storm of AI disruption, budget scrutiny and rising expectations from patients
More news about: WebMD Ignite
Oct 29, 2025, 08:11 ET AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your
More news about: AbbVie
Oct 27, 2025, 08:58 ET MIUDELLA® Hormone-Free Copper Intrauterine System (IUS) Phase 3 Data Publication in Contraception Honored with Daniel Mishell, Jr. MD Outstanding Article Award at Society of Family Planning Annual Meeting
MIUDELLA® may attach to or go through the uterus and cause other problems. Tell your healthcare provider (HCP) if you develop severe pain or fever shortly after placement, miss a period, have abdominal pain, or if MIUDELLA® comes out. If it comes out,
More news about: Sebela Pharmaceuticals Inc
Oct 27, 2025, 08:00 ET New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
& Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare provider (HCP) perspectives on barriers and unmet needs in psoriasis care. The results, presented at the 2025 Fall Clinical Dermatology Conference, reveal significant
More news about: Johnson & Johnson
Oct 27, 2025, 06:45 ET Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
in a single dose prefilled pen or prefilled syringe for subcutaneous injection. Refer to the Prescribing Information for dosing information. MR HCP ISI CD APP Click to access provided
More news about: Eli Lilly and Company
Oct 23, 2025, 09:00 ET HAVAS LYNX LAUNCHES NEW WHITE PAPER "DOCTORED TRUTHS" URGING PHARMA TO LEAD THE FIGHT AGAINST HEALTH MISINFORMATION
data solution from Havas Lynx, provides one of the most comprehensive global views of healthcare professional (HCP) attitudes, beliefs, behaviours, and influences to enable more powerful HCP strategies and experiences.
More news about: Havas Lynx
Oct 22, 2025, 09:00 ET ODAIA Introduces Brand Strategy Studio to Bridge the Gap Between Pharma Brand Planning and Commercial Execution
eliminating the disconnect between planning and execution. Brands can continually test approaches, simulate downstream impact on healthcare professional (HCP) segments and targets, call plans, and campaigns, and adapt to market changes in days instead of months.
More news about: ODAIA
Oct 21, 2025, 09:03 ET Figure 1 Named Best Healthcare & Medical Collaboration Network
"We're honored to receive an award that recognizes our commitment to building meaningful, collaborative case-based learning environments that strengthen HCP connection, accelerate knowledge sharing, and improve patient care." In addition to Figure 1, the Formedics ecosystem of digital,
More news about: Formedics, LLC
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your
More news about: AbbVie
Oct 17, 2025, 08:00 ET Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
Patient Information for Verzenio. AL HCP ISI 12OCT2021 About Lilly Lilly is a medicine company turning science into healing to make
More news about: Eli Lilly and Company
Oct 16, 2025, 08:09 ET Infosys: Quarterly revenue crosses $5 bn mark
Recognized as a leader in IDC MarketScape: Worldwide Life Sciences Healthcare Provider (HCP) Engagement Services 2025 Recognized as a leader in HFS Horizons: The Best Service Providers for Mortgage Reinvention, 2025
More news about: Infosys
Oct 16, 2025, 08:04 ET Infosys: Quarterly revenue crosses $5 bn mark
Recognized as a leader in IDC MarketScape: Worldwide Life Sciences Healthcare Provider (HCP) Engagement Services 2025 Recognized as a leader in HFS Horizons: The Best Service Providers for Mortgage Reinvention, 2025
More news about: Infosys
Oct 16, 2025, 08:01 ET PulsePoint Strengthens HCP Endemic Omnichannel Suite with Premium eNewsletters
health marketing technology company transforming how brands engage healthcare professionals (HCPs) and consumers, today announced the addition of premium HCP-targeted email newsletters (eNL) to its market-leading Endemic Omnichannel Suite. With this announcement, eNL inventory will now be programmatically
More news about: PulsePoint
Oct 16, 2025, 08:00 ET Sorcero Announces AI Guardrails, AI-Native Data Capture, and Insights Analytics to Transform Life Sciences Workflows
track insights by stage, monitor trends over time, view records-to-insights ratios, and analyze insights by evidence source, healthcare professional (HCP), therapeutic area, or owner/creator. This enhancement demonstrates how data transforms into actionable intelligence and helps Medical Affairs teams
More news about: Sorcero
Oct 15, 2025, 16:01 ET Sebela Women's Health's MIUDELLA® Hormone-Free Copper Intrauterine System (IUS) Named to TIME's List of the Best Inventions of 2025
MIUDELLA® may attach to or go through the uterus and cause other problems. Tell your healthcare provider (HCP) if you develop severe pain or fever shortly after placement, miss a period, have abdominal pain, or if MIUDELLA® comes out. If it
More news about: Sebela Pharmaceuticals Inc
Oct 14, 2025, 10:20 ET DataM Intelligence Facilitates Successful Vietnam Market Entry for Leading U.S. Probiotics Firm through Strategic Partner Identification
Fit – Evaluating alignment with probiotic categories and dosage forms. Medical Detailing & HCP/KOL Access – Analyzing strength in healthcare professional networks. Commercialization & Business
More news about: DataM Intelligence 4 Market Research LLP
Oct 13, 2025, 10:57 ET U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your
More news about: AbbVie
Oct 13, 2025, 06:45 ET Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
Patient Information for Verzenio. AL HCP ISI 12OCT2021 About Olomorasib Olomorasib (LY3537982) is an investigational,
More news about: Eli Lilly and Company